At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma.
ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma
26th June 2015
Hematology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given